Pune, Maharashtra -- (SBWire) -- 02/01/2017 --Vaginal Atrophy (Atrophic Vaginitis) Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics. Vaginal Atrophy (Atrophic Vaginitis) therapeutics industry report provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects.
Browse more detail information about Vaginal Atrophy (Atrophic Vaginitis) market report at: http://www.absolutereports.com/vaginal-atrophy-atrophic-vaginitis-pipeline-review-h2-2016-10435030
Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence. Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. Treatment includes topical (vaginal) estrogen and systemic estrogen therapy. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage
Key players in Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H2 2016:
- Allergan Plc
- EndoCeutics, Inc.
- Foamix Pharmaceuticals Ltd.
- Ligand Pharmaceuticals, Inc.
- Mithra Pharmaceuticals S.A.
- PEPTONIC medical AB
Get a PDF Sample of Vaginal Atrophy (Atrophic Vaginitis) Market Research Report at: http://www.absolutereports.com/enquiry/request-sample/10435030
Drug Profiles of Included in Vaginal Atrophy (Atrophic Vaginitis) Therapeutics Development Market Report
Estetrol
estradiol hemihydrate
lasofoxifene tartrate
And other drug profiles
Have any query? ask our expert @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10435030
Key Topics Covered:
1.Introduction
2.Vaginal Atrophy (Atrophic Vaginitis) Overview
3.Vaginal Atrophy (Atrophic Vaginitis) Therapeutics Development
4.Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Overview
5.Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Comparative Analysis
6.Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics under Development by Companies
7.Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics under Investigation by Universities/Institutes
8.Vaginal Atrophy (Atrophic Vaginitis) Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Vaginal Atrophy (Atrophic Vaginitis) - Products under Development by Companies
13.Vaginal Atrophy (Atrophic Vaginitis) - Products under Investigation by Universities/Institutes
14.Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development
15.Vaginal Atrophy (Atrophic Vaginitis) Drug Profiles
16.Vaginal Atrophy (Atrophic Vaginitis) Dormant Projects
17.Vaginal Atrophy (Atrophic Vaginitis) Discontinued Products
18.Vaginal Atrophy (Atrophic Vaginitis) Featured News & Press Releases
And Continue…
Get Discount on Vaginal Atrophy (Atrophic Vaginitis) Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10435030
This research study help to:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
About Absolute Report
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.
Vaginal Atrophy (Atrophic Vaginitis) Therapeutic Industry Pipeline Review H2 2016, Drug Profile and Major Key Players Analysis
Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H2 2016, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline landscape.